|
Zalcitabine
Zalcitabine (2′-3′-di deoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus ( HIV), and it has even been removed from pharmacies entirely in some countries. Medical uses Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It was approved on June 19, 1992, as a monotherapy and again in 1996 for use in combination with zidovudine (AZT). Using combinations of NRTIs was in practice prior to the second FDA a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Reverse-transcriptase Inhibitor
Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses. Mechanism of action When HIV infects a cell, reverse transcriptase copies the viral single stranded RNA genome into a double-stranded viral DNA. The viral DNA is then integrated into the host chromosomal DNA, which then allows host cellular processes, such as transcription and translation, to reproduce the virus. RTIs block reverse transcriptase's enzymatic function and prevent completion of synthesis of the double-stranded viral DNA, thus preventing HIV from multiplying. A similar process occurs with other types of viruses. The hepatitis B virus, for example, carries its genetic material in the form of DNA, and employs an RNA-dependent DNA polymerase to replicate. Some of the same compounds used as RTIs c ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Hiroaki Mitsuya
is a Japanese virologist famous for his role in discovery of the anti-HIV drug zidovudine (AZT) as well as other anti-AIDS drugs including didanosine (ddI) and zalcitabine (ddC). Mitsuya was born in Sasebo, Nagasaki and received his M.D. and Ph.D. from Kumamoto University. He joined the American National Cancer Institute in Bethesda, Maryland, in 1982, working initially on Human T-lymphotropic virus 1 before switching his attention to HIV. His identification of AZT as an anti-HIV drug, as well as the anti-HIV properties of didanosine and zalcitabine, was made in 1985. He was appointed Professor of Hematology, Rheumatology and Clinical Immunology at Kumamoto University Graduate School of Medical And Pharmaceutical Sciences. In December, 2006, he was awarded the first NIH The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. It was founded in 1887 and is part of the United States De ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Didanosine
Didanosine, sold under the brand name Videx among others, is a medication used to treat HIV/AIDS. It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991. Adverse effects The most common adverse events with didanosine are diarrhea, nausea, vomiting, abdominal pain, fever, headache, and rash. Peripheral neuropathy occurred in 21-26% of participants in key didanosine trials. Pancreatitis is rarely observed but has caused occasional fatalities, and has black box warning status. Other reported serious adverse events are retinal changes, optic neuritis and alterations of liver functions. The risk of some of these serious adverse events is increased by drinking alcohol. In February 2010, the United States Food and Drug Administration issued a statement that patients using didanosine (Videx) ar ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Robert Yarchoan
Robert Yarchoan (born 1950) is a medical researcher who played an important role in the development of the first effective drugs for AIDS. He is the Chief of the HIV and AIDS Malignancy Branch in the NCI and also coordinates HIV/AIDS malignancy research throughout the NCI as director of the Office of HIV and AIDS Malignancy (OHAM). Education and career Dr. Yarchoan was raised in Oceanside, New York and graduated from Amherst College in 1971. He subsequently received his M.D. from the University of Pennsylvania and completed an internship and residency in internal medicine at the University of Minnesota and a fellowship in Immunology in the Metabolism Branch of the NCI. After completing his training he joined the laboratory of Dr. Samuel Broder. In 1991 he was appointed to be a Section Chief of the Medicine Branch and in 1996 he named chief of the newly formed HIV and AIDS Malignancy Branch. Dr. Yarchoan was also appointed to be the first director of the NCI Office of HIV and A ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Samuel Broder
Samuel Broder (born in 1945) is an American oncologist and medical researcher. He was a co-developer of some of the first effective drugs for the treatment of AIDS and was Director of the National Cancer Institute (NCI) from 1989 to 1995. During the first years of the AIDS epidemic, he co-developed zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), which were the first effective drugs licensed for the treatment of AIDS. In 1989, he was appointed by President Ronald Reagan to be Director of the NCI. In this position he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics. He is now Chief Medical Officer of Celera. He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award. References ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Jerome Horwitz
Jerome Phillip Horwitz (January 16, 1919 – September 6, 2012) was an American scientist; his affiliations included the Barbara Ann Karmanos Cancer Institute, the Wayne State University School of Medicine and the Michigan Cancer Foundation. Background Horwitz was a Jewish Detroit native and 1937 graduate of Central High School. He earned his bachelor's and master's degrees in chemistry from the University of Detroit; his doctorate in chemistry came from the University of Michigan. He completed his post-doctoral training at Northwestern University and the University of Michigan Clinical breakthroughs In 1964, while conducting research for the Michigan Cancer Foundation, Horwitz synthesized a compound that was to become known as zidovudine (AZT) - an antiviral drug used to treat HIV patients; Zidovudine was initially developed as a treatment for cancer. Horwitz was also first to synthesize stavudine (d4T) and zalcitabine (ddC) - two other reverse-transcriptase inhibi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Analog (chemistry)
A structural analog, also known as a chemical analog or simply an analog, is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component. It can differ in one or more atoms, functional groups, or substructures, which are replaced with other atoms, groups, or substructures. A structural analog can be imagined to be formed, at least theoretically, from the other compound. Structural analogs are often isoelectronic. Despite a high chemical similarity, structural analogs are not necessarily functional analogs and can have very different physical, chemical, biochemical, or pharmacological properties. In drug discovery, either a large series of structural analogs of an initial lead compound are created and tested as part of a structure–activity relationship study or a database is screened for structural analogs of a lead compound. Chemical analogues of illegal drugs are developed and sold in order to circumvent la ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Stavudine
Stavudine (d4T), sold under the brand name Zerit among others, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. However, it is not a first-line treatment. It is given by mouth. Common side effects include headache, diarrhea, vomiting, rash, and peripheral nerve problems. Severe side effects include high blood lactate, pancreatitis, and an enlarged liver. It is not generally recommended in pregnancy. Stavudine is in the nucleoside analog reverse-transcriptase inhibitor (NRTI) class of medication. Stavudine was first described in 1966 and approved for use in the United States in 1994. It is available as a generic medication. Medical uses Stavudine is used in the treatment of HIV-1 infection, but is not a cure. It is not normally recommended as initial treatment. Stavudine can also reduce the risk of devel ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Zidovudine
Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein. Common side effects include headaches, fever, and nausea. Serious side effects include liver problems, muscle damage, and high blood lactate levels. It is commonly used in pregnancy and appears to be safe for the fetus. ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. Zidovudine was first described in 1964. It was resynthesize ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chain Elongation
A chain is a serial assembly of connected pieces, called links, typically made of metal, with an overall character similar to that of a rope in that it is flexible and curved in compression but linear, rigid, and load-bearing in tension. A chain may consist of two or more links. Chains can be classified by their design, which can be dictated by their use: * Those designed for lifting, such as when used with a hoist; for pulling; or for securing, such as with a bicycle lock, have links that are torus-shaped, which make the chain flexible in two dimensions (the fixed third dimension being a chain's length). Small chains serving as jewellery are a mostly decorative analogue of such types. * Those designed for transferring power in machines have links designed to mesh with the teeth of the sprockets of the machine, and are flexible in only one dimension. They are known as roller chains, though there are also non-roller chains such as block chains. Two distinct chains can be co ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Reverse Transcriptase
A reverse transcriptase (RT) is an enzyme used to convert RNA genome to DNA, a process termed reverse transcription. Reverse transcriptases are used by viruses such as HIV and hepatitis B to replicate their genomes, by retrotransposon mobile genetic elements to proliferate within the host genome, and by eukaryotic cells to extend the telomeres at the ends of their linear chromosomes. The process does not violate the flows of genetic information as described by the classical central dogma, but rather expands it to include transfers of information from RNA to DNA. Retroviral RT has three sequential biochemical activities: RNA-dependent DNA polymerase activity, ribonuclease H (RNase H), and DNA-dependent DNA polymerase activity. Collectively, these activities enable the enzyme to convert single-stranded RNA into double-stranded cDNA. In retroviruses and retrotransposons, this cDNA can then integrate into the host genome, from which new RNA copies can be made via host-cell ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
T Cell
T cells (also known as T lymphocytes) are an important part of the immune system and play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface receptor, cell surface. T cells are born from hematopoietic stem cells, found in the bone marrow. Developing T cells then migrate to the thymus gland to develop (or mature). T cells derive their name from the thymus. After migration to the thymus, the precursor cells mature into several distinct types of T cells. T cell differentiation also continues after they have left the thymus. Groups of specific, differentiated T cell subtypes have a variety of important functions in controlling and shaping the immune response. One of these functions is immune-mediated cell death, and it is carried out by two major subtypes: Cytotoxic T cell, CD8+ "killer" (cytotoxic) and T helper cell, CD4+ "helper" T cells. (These are named for the presen ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
